Skip to main content
DYN
NASDAQ Life Sciences

Major Shareholder Atlas Venture Files Intent to Sell Additional Shares and Discloses $28.5M in Recent Sales

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
7
Price
$18.84
Mkt Cap
$3.113B
52W Low
$8.06
52W High
$25
52W Position info
134% above low
Off High info
25% below high
Rel. Volume info
0.8× avg
Market data snapshot near publication time

DYN has more than doubled off its 52-week low of $8.06.

Summary

Atlas Venture, a major shareholder, has filed a Form 144 to sell additional shares and disclosed $28.5 million in recent sales, indicating continued distribution of its stake.


Key Events · Ownership and Investor Activity · DYN

  • Intent to Sell Additional Shares

    Atlas Venture Opportunity Fund II, LP filed a Form 144 indicating an intent to sell 21,926 common shares, valued at approximately $383,047.

  • Disclosure of Recent Sales

    The filing also disclosed that various Atlas Venture funds sold approximately $28.5 million worth of common stock between April 20 and May 5, 2026.

  • Significant Shareholder Distribution

    This ongoing selling activity by a major institutional investor represents a notable reduction in their holdings, potentially impacting market sentiment.


Analysis · DYN · Life Sciences

Atlas Venture Opportunity Fund II, LP, a significant shareholder, has filed a Form 144 indicating an intent to sell an additional 21,926 shares of Dyne Therapeutics common stock, valued at approximately $383,047. This filing also discloses a series of actual sales totaling approximately $28.5 million by various Atlas Venture funds between April 20 and May 5, 2026. This ongoing distribution by a major institutional investor, representing nearly 1% of the company's market capitalization, could signal a rebalancing of their portfolio or a reduction in their stake, potentially creating an overhang on the stock.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, DYN was trading at $18.84 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.1B. The 52-week trading range was $8.06 to $25.00. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

DYN - Latest Insights

DYN
Nov 05, 2026, 7:25 AM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $18.63
Real-time Price: $15.50 info
Change: -$3.13 (-17%) info
Market Cap: $2.904B info
DYN
Sep 29, 2026, 4:10 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $15.78
Real-time Price: $15.50 info
Change: -$0.280 (-2%) info
Market Cap: $2.904B info
DYN
Sep 29, 2026, 4:05 PM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $15.78
Real-time Price: $15.50 info
Change: -$0.280 (-2%) info
Market Cap: $2.904B info
DYN
Aug 17, 2026, 5:30 PM EDT
Filing Type: 4
Importance Score:
7
Price at Filing: $26.15
Real-time Price: $15.50 info
Change: -$10.65 (-41%) info
Market Cap: $2.904B info
DYN
Aug 14, 2026, 5:47 PM EDT
Filing Type: 144
Importance Score:
7
Price at Filing: $25.94
Real-time Price: $15.50 info
Change: -$10.44 (-40%) info
Market Cap: $2.904B info